(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are GENSIGHT BIOLOGICS, MARTIFER, and GROUPE JAJ.

Financial Asset	Price	Change	Updated (EST)
GENSIGHT BIOLOGICS (SIGHT.PA)	0.91	18.18%	2023-06-16 11:50:54
MARTIFER (MAR.LS)	1.37	14.17%	2023-06-16 08:19:04
GROUPE JAJ (GJAJ.PA)	1.43	10%	2023-06-16 11:51:15
POXEL (POXEL.PA)	0.73	8.64%	2023-06-16 11:01:57
AKER HORIZONS (AKH.OL)	8.56	8.35%	2023-06-16 08:20:17
ORPEA (ORP.PA)	2.59	7.74%	2023-06-16 11:01:21
CM.COM (CMCOM.AS)	9.81	7.33%	2023-06-16 11:01:31
SODITECH (SEC.PA)	1.52	7.04%	2023-06-16 11:03:33
ELECTROMAGNET GEO (EMGS.OL)	2.74	6.2%	2023-06-16 08:21:47
AKER CARBON CAPTUR (ACC.OL)	16.24	5.8%	2023-06-16 08:20:15

The three biggest losers today are BIOCARTIS, FONCIERE EURIS, and NHOA.

Financial Asset	Price	Change	Updated (EST)
BIOCARTIS (BCART.BR)	0.42	-21.5%	2023-06-16 11:06:33
FONCIERE EURIS (EURS.PA)	2.32	-17.14%	2023-06-16 11:50:01
NHOA (NHOA.PA)	3.91	-13.11%	2023-06-16 11:00:55
BARBARA BUI (BUI.PA)	8.60	-11.79%	2023-06-16 11:45:20
REINET INVESTMENTS (REINA.AS)	18.90	-10%	2023-06-16 11:04:35
BERGENBIO (BGBIO.OL)	0.29	-9.23%	2023-06-16 08:20:56
PCI BIOTECH HOLD (PCIB.OL)	2.27	-8.47%	2023-06-16 11:32:40
TEKNA HOLDING (TEKNA.OL)	7.04	-7.37%	2023-06-16 11:34:43
BENEVOLENTAI (BAI.AS)	1.54	-6.67%	2023-06-16 11:01:07
HOFSETH BIOCARE (HBC.OL)	2.72	-6.21%	2023-06-16 11:30:30

Winners today

1. GENSIGHT BIOLOGICS (SIGHT.PA)

18.18% Price Change

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.

CAC 40 ended the session with GENSIGHT BIOLOGICS jumping 18.18% to €0.91 on Friday, following the last session’s upward trend. CAC 40 jumped 1.34% to €7,388.65, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, GENSIGHT BIOLOGICS has a trailing twelve months EPS of €-0.59.

Volume

Today’s last reported volume for GENSIGHT BIOLOGICS is 537085 which is 26.23% above its average volume of 425458.

More news about GENSIGHT BIOLOGICS.

2. MARTIFER (MAR.LS)

14.17% Price Change

Martifer SGPS, S.A. operates in the metallic constructions and renewable energy development sectors worldwide. The company operates through Metallic Constructions, Naval Industry, and Renewables segments. The Metallic Constructions segment engages in the construction activities involving metal mechanical construction, aluminum, and glass façades, as well as infrastructures for oil and gas. The Naval Industry segment involved in shipbuilding, as well as provides ship repair services. The Renewables segment engages in the development of renewable energy projects, including wind and solar power projects. Martifer SGPS, S.A. was founded in 1990 and is headquartered in Oliveira de Frades, Portugal.

PSI ended the session with MARTIFER rising 14.17% to €1.37 on Friday, after two successive sessions in a row of gains. PSI jumped 0.61% to €6,075.98, after five successive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, MARTIFER has a trailing twelve months EPS of €0.15.

PE Ratio

MARTIFER has a trailing twelve months price to earnings ratio of 9.13. Meaning, the purchaser of the share is investing €9.13 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 53.03%.

Moving Average

MARTIFER’s worth is way higher than its 50-day moving average of €1.16 and way above its 200-day moving average of €1.12.

Volatility

MARTIFER’s last week, last month’s, and last quarter’s current intraday variation average was 3.75%, 0.21%, and 1.77%.

MARTIFER’s highest amplitude of average volatility was 3.75% (last week), 1.93% (last month), and 1.77% (last quarter).

Volume

Today’s last reported volume for MARTIFER is 186550 which is 1863.06% above its average volume of 9503.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MARTIFER’s stock is considered to be oversold (<=20).

More news about MARTIFER.

3. GROUPE JAJ (GJAJ.PA)

10% Price Change

Groupe JAJ distributes clothing products. It offers clothing products of the SCHOTT brand. The company was formerly known as JAJ Distribution. The company is headquartered in Montreuil, France.

CAC 40 ended the session with GROUPE JAJ jumping 10% to €1.43 on Friday while CAC 40 jumped 1.34% to €7,388.65.

Earnings Per Share

As for profitability, GROUPE JAJ has a trailing twelve months EPS of €0.24.

PE Ratio

GROUPE JAJ has a trailing twelve months price to earnings ratio of 5.96. Meaning, the purchaser of the share is investing €5.96 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GROUPE JAJ’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for GROUPE JAJ is 79 which is 92.51% below its average volume of 1055.

More news about GROUPE JAJ.

4. POXEL (POXEL.PA)

8.64% Price Change

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

CAC 40 ended the session with POXEL jumping 8.64% to €0.73 on Friday while CAC 40 rose 1.34% to €7,388.65.

Earnings Per Share

As for profitability, POXEL has a trailing twelve months EPS of €-1.14.

Volatility

POXEL’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.51%, a negative 0.85%, and a positive 2.23%.

POXEL’s highest amplitude of average volatility was 2.51% (last week), 2.17% (last month), and 2.23% (last quarter).

Moving Average

POXEL’s worth is higher than its 50-day moving average of €0.68 and way below its 200-day moving average of €1.15.

More news about POXEL.

5. AKER HORIZONS (AKH.OL)

8.35% Price Change

Aker Horizons ASA, through its subsidiaries, develops and invests in a portfolio of companies in the renewable energy and green technology comprising private and public companies worldwide. It sources, develops, structures, builds, and operates wind and solar power assets; and develops, builds, owns, and operates clean hydrogen production at industrial scale. The company also provides products, technology, and solutions within the field of carbon capture, utilization, and storage. In addition, it offers products and services to the hydropower industry; designs and delivers superconducting systems; and produces silicon materials. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Horizons ASA is a subsidiary of Aker Capital AS.

Oslo Børs Benchmark Index_GI ended the session with AKER HORIZONS rising 8.35% to €8.56 on Friday while Oslo Børs Benchmark Index_GI rose 0.86% to €1,246.02.

Earnings Per Share

As for profitability, AKER HORIZONS has a trailing twelve months EPS of kr-4.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.47%.

Yearly Top and Bottom Value

AKER HORIZONS’s stock is valued at kr8.56 at 22:40 EST, way below its 52-week high of kr21.74 and way higher than its 52-week low of kr6.93.

More news about AKER HORIZONS.

6. ORPEA (ORP.PA)

7.74% Price Change

ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. The company operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.

CAC 40 ended the session with ORPEA jumping 7.74% to €2.59 on Friday while CAC 40 jumped 1.34% to €7,388.65.

Earnings Per Share

As for profitability, ORPEA has a trailing twelve months EPS of €-62.33.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.36%.

More news about ORPEA.

7. CM.COM (CMCOM.AS)

7.33% Price Change

CM.com N.V. provides cloud software for conversational commerce worldwide. It operates in four segments: Communication Platform as a Service (CPaaS), Software as a Service (SaaS), Payment Services, and Ticketing. Its products include Mobile Service Cloud, an all-in-one customer service software; Conversational AI Cloud for automating customer service with AI powered chats and voice bots; Mobile Marketing Cloud, an omnichannel customer engagement solution for businesses; Ticketing that offers event, seated, and attraction ticketing services; Sign, which allows the user to complete contracts, agreements, and documents without printing and scanning; communications platform for mobile messaging and voice for business communication; and payments platform that accepts online and POS payments. CM.com N.V. was founded in 1999 and is headquartered in Breda, the Netherlands.

AEX-Index ended the session with CM.COM jumping 7.33% to €9.81 on Friday while AEX-Index jumped 0.01% to €772.72.

Earnings Per Share

As for profitability, CM.COM has a trailing twelve months EPS of €-1.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.1%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 17.8%, now sitting on 283.23M for the twelve trailing months.

Yearly Top and Bottom Value

CM.COM’s stock is valued at €9.81 at 22:40 EST, way under its 52-week high of €15.94 and way higher than its 52-week low of €7.71.

More news about CM.COM.

8. SODITECH (SEC.PA)

7.04% Price Change

Soditech SA engages in the integration of mechanical, thermal, and electronic sub-assemblies in space, research, and defense fields in France. It designs structural sub-assemblies and integrates optical and thermal equipment, such as OSRs, SSMs, heaters, and heat pipes; designs and manufactures multi-layer insulation products; and designs, manufactures, and tests space harnesses on instruments or platforms. The company also provides calculation services, such as static, dynamic, thermal, and thermoelastic; designs assembly tools; and designs and produces super insulating multi-layer mattresses for ultra-vacuum areas. In addition, it develops, qualifies, manufactures, and tests embedded cabinets; and designs, assembles, and tests racks and test equipment racks. The company was formerly known as Soditech Ingenierie SA. Soditech SA was founded in 1990 and is headquartered in Aix-en-Provence, France.

CAC 40 ended the session with SODITECH rising 7.04% to €1.52 on Friday, after four successive sessions in a row of losses. CAC 40 jumped 1.34% to €7,388.65, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, SODITECH has a trailing twelve months EPS of €0.12.

PE Ratio

SODITECH has a trailing twelve months price to earnings ratio of 12.67. Meaning, the purchaser of the share is investing €12.67 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.54%.

Yearly Top and Bottom Value

SODITECH’s stock is valued at €1.52 at 22:40 EST, way below its 52-week high of €1.73 and way above its 52-week low of €0.71.

Volume

Today’s last reported volume for SODITECH is 79 which is 79.04% below its average volume of 377.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SODITECH’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.7%, now sitting on 4.59M for the twelve trailing months.

More news about SODITECH.

9. ELECTROMAGNET GEO (EMGS.OL)

6.2% Price Change

Electromagnetic Geoservices ASA, together with its subsidiaries, provides electromagnetic (EM) surveying services to the offshore oil and gas exploration industry. It is involved in the planning, acquisition, processing, modelling, interpretation, and integration of EM data. The company uses its patented EM survey method to find hydrocarbons in offshore reservoirs. It engages in the provision of controlled-source EM surveying and magneto telluric surveying; imaging and interpretation; rental of software and cluster; and training services. The company has operations in Europe, the Middle East, Africa, Norway, North and South America, Asia, and the Pacific Ocean. Electromagnetic Geoservices ASA was incorporated in 2002 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ELECTROMAGNET GEO jumping 6.2% to €2.74 on Friday while Oslo Børs Benchmark Index_GI rose 0.86% to €1,246.02.

Earnings Per Share

As for profitability, ELECTROMAGNET GEO has a trailing twelve months EPS of kr0.83.

PE Ratio

ELECTROMAGNET GEO has a trailing twelve months price to earnings ratio of 3.3. Meaning, the purchaser of the share is investing kr3.3 for every norwegian krone of annual earnings.

Volume

Today’s last reported volume for ELECTROMAGNET GEO is 256276 which is 47.5% below its average volume of 488199.

More news about ELECTROMAGNET GEO.

10. AKER CARBON CAPTUR (ACC.OL)

5.8% Price Change

Aker Carbon Capture ASA provides products, technology, and solutions within the field of carbon capture technologies, utilization, and storage in Norway and internationally. The company's carbon capture process uses a mixture of water and organic amine solvents to absorb the CO2 that can be applied on emissions from various sources, including gas, coal, cement, refineries, and waste-to-energy through to hydrogen and other process industries. It offers carbon capture plants under the Just Catch and Big Catch brands. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Carbon Capture ASA is a subsidiary of Aker Horizons Holding AS.

Oslo Børs Benchmark Index_GI ended the session with AKER CARBON CAPTUR rising 5.8% to €16.24 on Friday while Oslo Børs Benchmark Index_GI rose 0.86% to €1,246.02.

Earnings Per Share

As for profitability, AKER CARBON CAPTUR has a trailing twelve months EPS of kr-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.91%.

Sales Growth

AKER CARBON CAPTUR’s sales growth is 49.8% for the ongoing quarter and 42.4% for the next.

More news about AKER CARBON CAPTUR.

Losers Today

1. BIOCARTIS (BCART.BR)

-21.5% Price Change

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

BEL 20 ended the session with BIOCARTIS dropping 21.5% to €0.42 on Friday, after five successive sessions in a row of losses. BEL 20 slid 0% to €3,658.43, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, BIOCARTIS has a trailing twelve months EPS of €-1.06.

Volatility

BIOCARTIS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.99%, a negative 0.45%, and a positive 1.77%.

BIOCARTIS’s highest amplitude of average volatility was 0.99% (last week), 1.25% (last month), and 1.77% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOCARTIS’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for BIOCARTIS is 2403100 which is 2298.81% above its average volume of 100179.

More news about BIOCARTIS.

2. FONCIERE EURIS (EURS.PA)

-17.14% Price Change

Foncière Euris SA distributes food and specialized products in France and internationally. The company also owns real estate assets, including shopping centers; and manages commercial real estate properties and private equity portfolio. The company was incorporated in 1970 and is based in Paris, France. Foncière Euris SA operates as a subsidiary of Finatis Société Anonyme.

CAC 40 ended the session with FONCIERE EURIS falling 17.14% to €2.32 on Friday, after three sequential sessions in a row of gains. CAC 40 jumped 1.34% to €7,388.65, following the last session’s downward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, FONCIERE EURIS has a trailing twelve months EPS of €-16.88.

Volume

Today’s last reported volume for FONCIERE EURIS is 199 which is 60.35% below its average volume of 502.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FONCIERE EURIS’s stock is considered to be oversold (<=20).

More news about FONCIERE EURIS.

3. NHOA (NHOA.PA)

-13.11% Price Change

NHOA S.A. provides energy storage, E-mobility, and EV fastcharging infrastructure related solutions in France. The company offers solar plus storage, utility-scale storage, and industrial microgrids. It also provides charging services and devices for electric and hybrid vehicles. In addition, the company offers power house, and hybrid house; and HyESS, a technology platform for the transformation of renewables into sustainable grids, as well as Atlante, an eStation that provides fast charging solution. NHOA S.A. is based in Paris, France.

CAC 40 ended the session with NHOA falling 13.11% to €3.91 on Friday, following the last session’s downward trend. CAC 40 jumped 1.34% to €7,388.65, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, NHOA has a trailing twelve months EPS of €-1.49.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -58.43%.

Yearly Top and Bottom Value

NHOA’s stock is valued at €3.91 at 22:40 EST, way below its 52-week high of €14.06 and way above its 52-week low of €3.15.

Moving Average

NHOA’s worth is way below its 50-day moving average of €4.51 and way below its 200-day moving average of €8.25.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NHOA’s stock is considered to be oversold (<=20).

More news about NHOA.

4. BARBARA BUI (BUI.PA)

-11.79% Price Change

Barbara Bui SA engages in the manufacture, marketing, and sale of ready-to-wear clothing and accessories for women in France and internationally. The company offers jackets, tops and shirts, T-shirts, pants, dresses and skirts, coats, leather products, mesh, and tailored cloths; shoes; bags; and accessories, such as scarves, belts, card holder and key ring, wallets, and jewelries. It offers its products through wholesale distributors, as well as online and offline stores. The company was founded in 1983 and is based in Paris, France.

CAC 40 ended the session with BARBARA BUI falling 11.79% to €8.60 on Friday, after five consecutive sessions in a row of losses. CAC 40 rose 1.34% to €7,388.65, following the last session’s downward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, BARBARA BUI has a trailing twelve months EPS of €1.61.

PE Ratio

BARBARA BUI has a trailing twelve months price to earnings ratio of 5.34. Meaning, the purchaser of the share is investing €5.34 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.8%.

Yearly Top and Bottom Value

BARBARA BUI’s stock is valued at €8.60 at 22:40 EST, way under its 52-week high of €10.50 and way above its 52-week low of €6.30.

Volume

Today’s last reported volume for BARBARA BUI is 37 which is 27.58% above its average volume of 29.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.9%, now sitting on 10.92M for the twelve trailing months.

Moving Average

BARBARA BUI’s worth is way above its 50-day moving average of €7.53 and way higher than its 200-day moving average of €7.52.

More news about BARBARA BUI.

5. REINET INVESTMENTS (REINA.AS)

-10% Price Change

Reinet Investments S.C.A. operates as a securitization vehicle in Luxembourg. The company, through its subsidiary, Reinet Fund S.C.A., F.I.S., invests in assets. Reinet Investments Manager S.A. operates as a general partner of Reinet Investments S.C.A. The company was formerly known as Richemont S.A. and changed its name to Reinet Investments S.C.A. in October 2008. Reinet Investments S.C.A. was incorporated in 1979 and is based in Luxembourg.

AEX-Index ended the session with REINET INVESTMENTS dropping 10% to €18.90 on Friday, after two sequential sessions in a row of gains. AEX-Index jumped 0.01% to €772.72, after four consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, REINET INVESTMENTS has a trailing twelve months EPS of €-0.67.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, REINET INVESTMENTS’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for REINET INVESTMENTS is 5 which is 98.7% below its average volume of 386.

Volatility

REINET INVESTMENTS’s last week, last month’s, and last quarter’s current intraday variation average was 1.96%, 0.15%, and 2.25%.

REINET INVESTMENTS’s highest amplitude of average volatility was 1.96% (last week), 2.30% (last month), and 2.25% (last quarter).

More news about REINET INVESTMENTS.

6. BERGENBIO (BGBIO.OL)

-9.23% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO dropping 9.23% to €0.29 on Friday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 0.86% to €1,246.02, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-2.86.

More news about BERGENBIO.

7. PCI BIOTECH HOLD (PCIB.OL)

-8.47% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD falling 8.47% to €2.27 on Friday while Oslo Børs Benchmark Index_GI rose 0.86% to €1,246.02.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.11.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.97%.

More news about PCI BIOTECH HOLD.

8. TEKNA HOLDING (TEKNA.OL)

-7.37% Price Change

Tekna Holding ASA develops, manufactures, and sells micro and nano powders, and plasma process solutions in North America, Europe, Asia, and internationally. The company offers spherical powders, such as titanium, nickel, and aluminum alloys, as well as tungsten and tantalum; and nanopowders, including nickel nanopowder, silicon nanopowder, copper nanopowder, and boron nitride nanotubes for use in additive manufacturing, metal injection molding, thermal spray, and hot isostatic pressing. It serves aviation, aerospace, medical, mining and drilling, energy storage, and microelectronics industries. The company was founded in 1990 and is headquartered in Sherbrooke, Canada. Tekna Holding ASA is a subsidiary of Arendals Fossekompani ASA.

Oslo Børs Benchmark Index_GI ended the session with TEKNA HOLDING sliding 7.37% to €7.04 on Friday while Oslo Børs Benchmark Index_GI jumped 0.86% to €1,246.02.

Earnings Per Share

As for profitability, TEKNA HOLDING has a trailing twelve months EPS of kr-1.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.23%.

Yearly Top and Bottom Value

TEKNA HOLDING’s stock is valued at kr7.04 at 22:40 EST, way below its 52-week high of kr20.00 and way above its 52-week low of kr5.30.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TEKNA HOLDING’s stock is considered to be oversold (<=20).

Moving Average

TEKNA HOLDING’s worth is way above its 50-day moving average of kr6.39 and way below its 200-day moving average of kr7.88.

More news about TEKNA HOLDING.

9. BENEVOLENTAI (BAI.AS)

-6.67% Price Change

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI falling 6.67% to €1.54 on Friday while AEX-Index rose 0.01% to €772.72.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-1.68.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -152.53%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 93.1%, now sitting on 10.56M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BENEVOLENTAI’s stock is considered to be overbought (>=80).

More news about BENEVOLENTAI.

10. HOFSETH BIOCARE (HBC.OL)

-6.21% Price Change

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.

Oslo Børs Benchmark Index_GI ended the session with HOFSETH BIOCARE dropping 6.21% to €2.72 on Friday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 0.86% to €1,246.02, after two sequential sessions in a row of losses, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -126.49%.

Volatility

HOFSETH BIOCARE’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.44%, a negative 0.58%, and a positive 3.29%.

HOFSETH BIOCARE’s highest amplitude of average volatility was 3.44% (last week), 2.93% (last month), and 3.29% (last quarter).

Moving Average

HOFSETH BIOCARE’s worth is way under its 50-day moving average of kr3.13 and way below its 200-day moving average of kr3.06.

Revenue Growth

Year-on-year quarterly revenue growth grew by 45.4%, now sitting on 134.43M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

HOFSETH BIOCARE’s EBITDA is 8.78.

More news about HOFSETH BIOCARE.

Stay up to date with our winners and losers daily report